David Southwell is a finance expert with a B.A. from Rice University and an M.B.A. from the Tuck School at Dartmouth College. He served as the CEO of TScan Therapeutics, Inc. from April 2018 until March 2023. Under his leadership,...
David Southwell is a finance expert with a B.A. from Rice University and an M.B.A. from the Tuck School at Dartmouth College. He served as the CEO of TScan Therapeutics, Inc. from April 2018 until March 2023. Under his leadership, the company focused on innovative therapies for cancer and other diseases. Interestingly, he stepped down without cause, which meant he received severance pay totaling $1,003,724 as part of his exit. Despite having no vested stock during 2023 due to his departure, he had a history of significant insider trading, with his wealth in TScan stock peaking at around $5.72 million in early 2021. His last compensation package for 2022 included a base salary of $622,239 with an additional performance-based cash bonus. Southwell’s exit marked a transitional phase for TScan as they welcomed new leadership, but his tenure shaped the strategic direction of the company into the realm of cutting-edge biotechnology.